PPT-The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between

Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier Institut Jacques Cartier Massy France Patrick W Serruys Imperial College London UK. A clinical evaluation to compare the safety efficacy and performance of the Absorb everolimuseluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects wit CS648. . Lecture 3. Two fundamental problems. Balls into bins. Randomized Quick Sort. Random Variable and Expected . value. 1. Balls into BINS. Calculating probability of some interesting events. 2. The ABSORB III trial. Dean J. Kereiakes, MD, . Stephen . G. Ellis, MD, D. Christopher Metzger, MD, Ronald P. Caputo, MD, David G. Rizik, MD, Paul S. Teirstein, MD, Marc R. . Litt. , MD, . Annapoorna. clinico. in . tema. di BVS. Bernardo Cortese. Intv. ’ . Cardiology. , A.O. Fatebenefratelli. bcortese@gmail.com. b. ernardocortese.com. Bernardo Cortese MD FESC. A.O. Fatebenefratelli. The ABSORB Clinical Trial Program. Comparison of . Everolimus-­. Eluting . Absorb Bioresorbable Vascular. Scaffolds vs. . Everolimus-Eluting Metallic. . Stents:. One-Year Angiographic and Clinical Outcomes from the ABSORB China Trial. Susan S. . Ellenberg. , Ph.D.. University of Pennsylvania. SCT/ICTMC Joint Meeting. Liverpool, UK. May 8, 2017. CLINICAL TRIALS TIMELINE. 1948: First randomized clinical trials of modern era. 1962: Amendments to U.S. Food, Drug and Cosmetic Act requiring demonstration of efficacy as well as safety. Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. COMPARISON OF ADJECTIVES DEGREES OF COMPARISON DEGREES OF COMPARISON COMPARATIVE DEGREE (Grau Comparativo) Compara UM elemento com OUTRO . Nessa comparação poderá haver IGUALDADE, DESIGUALDADE, SUPERIORIDADE WHAT IS A BIOSTATISTICIAN TRYING TO PROVE? PROOF IN MEDICAL RESEARCH Susan S. Ellenberg , Ph.D. Department of Biostatistics and Epidemiology Perelman School of Medicine, U Penn Statistics is the science of uncertainty Results in Patients with Coronary Artery Disease Randomized to the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stents. Runlin . Gao, M.D.. On behalf of ABSORB China Investigators. vs. 1.46 mm, . p < 0.0001; . IVUS showed lower post-procedure mean lumen area in BVS arm (4.9 vs. 5.7 mm. 2. , . p < 0.001. ). 1-year scaffold thrombosis in . two . BVS . patients; . no stent thrombosis in DES arm. Michel Cucherat. Lyon. Liens d’intérêt en oncologie. BMS, MSD, Bayer, Novartis, . Gilead. Finalité pratique. Identifier si un essai thérapeutique démontre ou non l’intérêt clinique d’un nouveau traitement. Training course in research methodology and research protocol development. Geneva 2021. Dr Khalifa Elmusharaf . MBBS, PgDip, FRSPH, PHD. Senior Lecturer in Public Health. Director of Public Health Master Programme. Low-risk Randomized Trial. Michael J. Mack, . MD & . Martin B. Leon, MD. on behalf of the PARTNER 3 Trial Investigators. Disclosures - Michael J. Mack, MD. ACC 2020; Chicago, IL; March 28–30, 2020.